Tags

Type your tag names separated by a space and hit enter

Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar.
Indian J Med Res. 1993 Jul; 97:170-5.IJ

Abstract

A total of 150 patients of kala-azar matched for age and sex and parasitologically proved were randomly allocated to two equal treatment groups. Patients in one group received amphotericin B(AMB) in a dose of 1 mg/kg body weight (BW) on alternate days starting with 0.05 mg/kg/bw on first day with daily increments, till a total dose of 20 mg/kg/bw was given; the patients in the second group received sodium stibogluconate (SAG) in the dose of 20 mg/kg/bw, im daily for 30 days. The efficacy, safety and cost-effectiveness of the two drugs were compared. Apparent cure (afebrile at the end of therapy) in 75 (100%) and 69 (92%) patients and ultimate cure (no relapse in six months of follow up) in 75 (100%) and 60 (80%) patients occurred in the AMB and SAG groups respectively. The difference between the ultimate cure in the two groups was significant (P < 0.001). Six (8%) and 9(12%) patients of SAG group showed primary (with no response to SAG during treatment) and secondary unresponsiveness (with no response to SAG after relapse) respectively and they were cured with amphotericin B.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Thakur CP
Department of Medicine, Medical College, Patna.
Sinha GP
No affiliation info available
Sharma V
No affiliation info available
Pandey AK
No affiliation info available
Kumar M
No affiliation info available
Verma BB
No affiliation info available

MeSH

AdolescentAdultAmphotericin BAntimony Sodium GluconateFemaleHumansIndiaLeishmaniasis, VisceralMale

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8406644

Citation

Thakur, C P., et al. "Evaluation of Amphotericin B as a First Line Drug in Comparison to Sodium Stibogluconate in the Treatment of Fresh Cases of Kala-azar." The Indian Journal of Medical Research, vol. 97, 1993, pp. 170-5.
Thakur CP, Sinha GP, Sharma V, et al. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian J Med Res. 1993;97:170-5.
Thakur, C. P., Sinha, G. P., Sharma, V., Pandey, A. K., Kumar, M., & Verma, B. B. (1993). Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. The Indian Journal of Medical Research, 97, 170-5.
Thakur CP, et al. Evaluation of Amphotericin B as a First Line Drug in Comparison to Sodium Stibogluconate in the Treatment of Fresh Cases of Kala-azar. Indian J Med Res. 1993;97:170-5. PubMed PMID: 8406644.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. AU - Thakur,C P, AU - Sinha,G P, AU - Sharma,V, AU - Pandey,A K, AU - Kumar,M, AU - Verma,B B, PY - 1993/7/1/pubmed PY - 1993/7/1/medline PY - 1993/7/1/entrez SP - 170 EP - 5 JF - The Indian journal of medical research JO - Indian J Med Res VL - 97 N2 - A total of 150 patients of kala-azar matched for age and sex and parasitologically proved were randomly allocated to two equal treatment groups. Patients in one group received amphotericin B(AMB) in a dose of 1 mg/kg body weight (BW) on alternate days starting with 0.05 mg/kg/bw on first day with daily increments, till a total dose of 20 mg/kg/bw was given; the patients in the second group received sodium stibogluconate (SAG) in the dose of 20 mg/kg/bw, im daily for 30 days. The efficacy, safety and cost-effectiveness of the two drugs were compared. Apparent cure (afebrile at the end of therapy) in 75 (100%) and 69 (92%) patients and ultimate cure (no relapse in six months of follow up) in 75 (100%) and 60 (80%) patients occurred in the AMB and SAG groups respectively. The difference between the ultimate cure in the two groups was significant (P < 0.001). Six (8%) and 9(12%) patients of SAG group showed primary (with no response to SAG during treatment) and secondary unresponsiveness (with no response to SAG after relapse) respectively and they were cured with amphotericin B.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0971-5916 UR - https://www.unboundmedicine.com/medline/citation/8406644/Evaluation_of_amphotericin_B_as_a_first_line_drug_in_comparison_to_sodium_stibogluconate_in_the_treatment_of_fresh_cases_of_kala_azar_ DB - PRIME DP - Unbound Medicine ER -